Madhu Kumar
Stock Analyst at Goldman Sachs
(2.86)
# 1,691
Out of 4,876 analysts
155
Total ratings
55.34%
Success rate
18.52%
Average return
Main Sectors:
Stocks Rated by Madhu Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Initiates: Buy | $169 | $107.59 | +57.08% | 7 | Jun 5, 2024 | |
| FULC Fulcrum Therapeutics | Maintains: Neutral | $5 → $6 | $7.38 | -18.70% | 8 | Jan 26, 2024 | |
| INFA Informatica | Maintains: Neutral | $23 → $26 | $24.35 | +6.78% | 5 | Dec 7, 2023 | |
| UTZ Utz Brands | Maintains: Neutral | $19 → $17 | $12.75 | +33.33% | 2 | Nov 10, 2023 | |
| ALEC Alector | Initiates: Sell | $4 | $1.50 | +166.67% | 4 | Sep 25, 2023 | |
| KRYS Krystal Biotech | Maintains: Buy | $135 → $155 | $142.69 | +8.63% | 13 | May 22, 2023 | |
| CYTK Cytokinetics | Maintains: Buy | $48 → $53 | $33.91 | +56.30% | 4 | May 5, 2023 | |
| DSGN Design Therapeutics | Upgrades: Neutral | n/a | $3.82 | - | 3 | May 4, 2023 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $65 → $73 | $16.07 | +354.26% | 10 | May 3, 2023 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $124 → $141 | $18.40 | +666.30% | 9 | Apr 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $39 → $34 | $9.29 | +265.98% | 6 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $1.74 | +244.83% | 8 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $14 | $14.41 | -2.85% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $21 | $9.94 | +111.37% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $5 | $13.06 | -61.72% | 3 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $10 → $8 | $2.12 | +277.36% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $111 → $89 | $7.80 | +1,041.03% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $6 | $0.33 | +1,718.18% | 1 | Jan 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $10 | $0.38 | +2,531.58% | 1 | Aug 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $85 | $9.61 | +784.50% | 7 | Jun 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $23 → $39 | $1.49 | +2,521.32% | 3 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $58 → $57 | $14.23 | +300.56% | 3 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.20 | - | 15 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $1.75 | +51,255.21% | 1 | Apr 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $17 → $20 | $5.31 | +276.65% | 2 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $1.17 | +8,447.01% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $35.48 | -1.35% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $60 | $0.28 | +21,351.56% | 1 | Feb 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $40 | $10.37 | +285.73% | 2 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $504 | $17.08 | +2,850.82% | 3 | Oct 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $230 | $318.25 | -27.73% | 2 | Aug 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $120 → $60 | $8.16 | +635.29% | 5 | Jul 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 → $1,125 | $16.90 | +6,556.80% | 2 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $0.83 | +4,704.23% | 1 | Feb 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $22 | $37.95 | -43.35% | 1 | Dec 1, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $46.70 | -49.68% | 1 | Mar 28, 2017 |
Jazz Pharmaceuticals
Jun 5, 2024
Initiates: Buy
Price Target: $169
Current: $107.59
Upside: +57.08%
Fulcrum Therapeutics
Jan 26, 2024
Maintains: Neutral
Price Target: $5 → $6
Current: $7.38
Upside: -18.70%
Informatica
Dec 7, 2023
Maintains: Neutral
Price Target: $23 → $26
Current: $24.35
Upside: +6.78%
Utz Brands
Nov 10, 2023
Maintains: Neutral
Price Target: $19 → $17
Current: $12.75
Upside: +33.33%
Alector
Sep 25, 2023
Initiates: Sell
Price Target: $4
Current: $1.50
Upside: +166.67%
Krystal Biotech
May 22, 2023
Maintains: Buy
Price Target: $135 → $155
Current: $142.69
Upside: +8.63%
Cytokinetics
May 5, 2023
Maintains: Buy
Price Target: $48 → $53
Current: $33.91
Upside: +56.30%
Design Therapeutics
May 4, 2023
Upgrades: Neutral
Price Target: n/a
Current: $3.82
Upside: -
Arrowhead Pharmaceuticals
May 3, 2023
Maintains: Buy
Price Target: $65 → $73
Current: $16.07
Upside: +354.26%
Apellis Pharmaceuticals
Apr 14, 2023
Maintains: Buy
Price Target: $124 → $141
Current: $18.40
Upside: +666.30%
Mar 1, 2023
Maintains: Buy
Price Target: $39 → $34
Current: $9.29
Upside: +265.98%
Dec 9, 2022
Downgrades: Neutral
Price Target: $20 → $6
Current: $1.74
Upside: +244.83%
Nov 10, 2022
Maintains: Sell
Price Target: $8 → $14
Current: $14.41
Upside: -2.85%
Nov 4, 2022
Maintains: Buy
Price Target: $24 → $21
Current: $9.94
Upside: +111.37%
Aug 25, 2022
Downgrades: Sell
Price Target: $5
Current: $13.06
Upside: -61.72%
May 24, 2022
Maintains: Sell
Price Target: $10 → $8
Current: $2.12
Upside: +277.36%
May 24, 2022
Maintains: Buy
Price Target: $111 → $89
Current: $7.80
Upside: +1,041.03%
Jan 19, 2022
Downgrades: Neutral
Price Target: $29 → $6
Current: $0.33
Upside: +1,718.18%
Aug 27, 2021
Downgrades: Sell
Price Target: $10
Current: $0.38
Upside: +2,531.58%
Jun 23, 2021
Maintains: Neutral
Price Target: $60 → $85
Current: $9.61
Upside: +784.50%
Mar 16, 2021
Upgrades: Outperform
Price Target: $23 → $39
Current: $1.49
Upside: +2,521.32%
Jul 31, 2020
Upgrades: Outperform
Price Target: $58 → $57
Current: $14.23
Upside: +300.56%
Jul 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $3.20
Upside: -
Apr 21, 2020
Initiates: Outperform
Price Target: $900
Current: $1.75
Upside: +51,255.21%
Mar 27, 2020
Maintains: Underperform
Price Target: $17 → $20
Current: $5.31
Upside: +276.65%
Mar 13, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $1.17
Upside: +8,447.01%
Mar 12, 2020
Initiates: Outperform
Price Target: $35
Current: $35.48
Upside: -1.35%
Feb 11, 2020
Initiates: Outperform
Price Target: $60
Current: $0.28
Upside: +21,351.56%
Sep 24, 2019
Maintains: Buy
Price Target: $58 → $40
Current: $10.37
Upside: +285.73%
Oct 8, 2018
Upgrades: Buy
Price Target: $504
Current: $17.08
Upside: +2,850.82%
Aug 13, 2018
Maintains: Buy
Price Target: $210 → $230
Current: $318.25
Upside: -27.73%
Jul 6, 2018
Maintains: Neutral
Price Target: $120 → $60
Current: $8.16
Upside: +635.29%
Feb 9, 2018
Maintains: Buy
Price Target: $150 → $1,125
Current: $16.90
Upside: +6,556.80%
Feb 8, 2018
Initiates: Buy
Price Target: $40
Current: $0.83
Upside: +4,704.23%
Dec 1, 2017
Reinstates: Buy
Price Target: $22
Current: $37.95
Upside: -43.35%
Mar 28, 2017
Initiates: Buy
Price Target: $24
Current: $46.70
Upside: -49.68%